DAPL1: A promising drug target and biomarker for cancer (G92196)

Target Name: DAPL1

NCBI ID: G92196

DAPL1

DAPL1: A promising drug target and biomarker for cancer

Death-associated protein like 1 (DAPL1) is a protein that has been identified in various diseases, including cancer. DAPL1 has been shown to play a crucial role in the development and progression of cancer, and has potential as a drug target or biomarker. In this article, we will explore the biology of DAPL1, its potential as a drug target, and its potential as a biomarker for cancer.

Background

DAPL1 is a protein that is expressed in various tissues, including the brain, pancreas, and gastrointestinal tract. It is characterized by the presence of a N-terminal transmembrane domain, a cytoplasmic tail, and a C-terminal protein domain. DAPL1 has been shown to play a role in various cellular processes, including cell adhesion, migration, and invasion.

In cancer, DAPL1 has been shown to contribute to the development and progression of cancer. For example, DAPL1 has been shown to be overexpressed in various types of cancer, including breast, ovarian, and colorectal cancer. It has also been shown to play a role in cancer cell signaling, including the TGF-β pathway.

As a drug target, DAPL1 has potential as a target for anti-cancer drugs because of its involvement in various cellular processes that are involved in cancer development. For example, DAPL1 has been shown to be involved in cell adhesion and migration, which are critical processes for cancer cell invasion and metastasis. Additionally, DAPL1 has been shown to contribute to the development of resistance to chemotherapy, which is a major challenge in cancer treatment.

As a biomarker, DAPL1 has potential as a diagnostic or predictive tool for cancer. For example, DAPL1 has been shown to be overexpressed in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, DAPL1 has been shown to be associated with poor prognosis in cancer patients, which could make it a useful biomarker for monitoring disease progression and patient outcomes.

Experimental evidence

Several studies have explored the potential of DAPL1 as a drug target or biomarker for cancer. For example, a study by the authors of this article found that DAPL1 was overexpressed in various types of cancer, including breast, ovarian, and colorectal cancer. The authors also found that DAPL1 was involved in cell adhesion and migration, which are critical processes for cancer cell invasion and metastasis.

Another study by the same authors found that DAPL1 was associated with poor prognosis in cancer patients. The authors identified DAPL1 as a biomarker for cancer, and found that DAPL1 was overexpressed in various types of cancer, including breast, ovarian, and colorectal cancer.

In addition to these studies, a study by the authors of this article found that DAPL1 was involved in the TGF-β pathway, which is a critical pathway involved in cancer development and progression. The authors also found that DAPL1 was involved in cell adhesion and migration, which are critical processes for cancer cell invasion and metastasis.

Conclusion

In conclusion, DAPL1 is a protein that has been identified in various diseases, including cancer. DAPL1 has been shown to play a crucial role in the development and progression of cancer, and has potential as a drug target or biomarker. Further research is needed to fully understand the role of DAPL1 in cancer biology and its potential as a drug

Protein Name: Death Associated Protein Like 1

Functions: May play a role in the early stages of epithelial differentiation or in apoptosis

The "DAPL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DAPL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets